Multiple myeloma is characterized by the proliferation and accumulation of malignant plasma cells in the bone marrow and has been shown to be preceded by the premalignant states of either monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma.
1 Currently, markers that predict progression to multiple myeloma are dependent on clinical variables that are influenced by the timing of diagnosis. Moreover, it was recently shown that the risk of progression is dynamic, with evolving risk patterns supporting close follow-up of patients.
2 Smoldering myeloma has a risk of progression that is higher than that of MGUS and can be risk stratified using the Mayo Clinic, Programa de Estudio y Tratamiento de las Hemopatías Malignas (PETHEMA), and/or the criteria set forth by Rajkumar, Landgren, and Mateos.
3-7 Using these risk models, patients with high-risk smoldering myeloma have an approximately 75% risk of developing symptomatic multiple myeloma at 5 years and a median time to progression of less than 2 years.